FindTrial
Sign In

The effect of prevention and treatment on revascularization for ischemic heart failure

The effect of prevention and treatment on revascularization for ischemic heart failure

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-PRCH-13003570
Enrollment
Unknown
Registered
2013-09-05
Start date
2013-10-08
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Revascularization Group:Peripheral venous blood collection and Echocardiog
No Revascularization Group:Peripheral venous blood collection and Echocardiog

Sponsors

First Affiliated Hospital of the Xi’an Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Clear diagnosis of STEMI patients, or patients who have a clear history of STEMI; 3. Enrolled January 2009-December 2011 hospitalized cases.

Exclusion criteria

Exclusion criteria: 1. With primary cardiomyopathy, rheumatic valvular heart disease, congenital heart disease, and others may cause heart enlargement and heart failure patients; 2. Merger blood diseases, autoimmune diseases, cancer, and other systems of acute and chronic diseases; 3. Patients with severe liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Echocardiography;MMP1;MMP2;MMP3;MMP9;TIMP1;TIMP2;hs-CRP;TNF-a;IL-1;IL-6;IL-10;NT-proBNP;PICP;ICT;—

Countries

China

Contacts

Public ContactMa Ai-qun

Department of Cardiovascular Medicine, First Affiliated Hospital of the Xi’an Jiaotong University School of Medicine

maaiqun@medmail.com.cn+86 29-85323568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026